Across TCGA pan-cancer cohorts, BICD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BICD2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BICD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BICD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and GBM are the cancer types where BICD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.862	0.677	.005	46	view →
PDAC	OS	Tertile	II,III,IV	0.362	0.688	.002	37	view →
GBM	DFS	Tertile	All	0.226	0.453	.002	14	view →
LSCC	DFS	Median	II,III,IV	0.822	0.566	.012	10	view →
LUAD	OS	Quartile	All	0.753	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BICD2 tumor-vs-normal RNA expression · all BICD2 data types